Inibikase Therapeutics, Inc. (IKT): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem em rápida evolução da pesquisa de doenças neurodegenerativas, a Inibikase Therapeutics, Inc. (IKT) surge como uma força pioneira, empunhando uma sofisticada plataforma de tecnologia de inibição da enzima que promete revolucionar nosso entendimento e tratamento de condições neurológicas complexas. Ao preencher estrategicamente pesquisas científicas de ponta, intervenções moleculares inovadoras e abordagens de medicina de precisão, a IKT está se posicionando na vanguarda de possíveis terapias inovadoras para a doença de Parkinson e os distúrbios neurológicos relacionados. Sua abrangente modelo de negócios Canvas revela uma estratégia meticulosamente criada que combina excelência científica, parcerias estratégicas e um compromisso implacável em atender às necessidades médicas não atendidas no domínio desafiador da pesquisa neurodegenerativa.

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para colaborações de desenvolvimento de medicamentos

Instituição	Foco de colaboração	Ano estabelecido
Universidade de Pittsburgh	Pesquisa de doenças de Parkinson	2018
Instituto de Tecnologia da Geórgia	Terapêutica da doença neurodegenerativa	2019

Empresas farmacêuticas para suporte ao ensaio clínico

A Inibikase estabeleceu parcerias estratégicas com organizações de apoio aos ensaios clínicos:

• Syneos Health - Serviços de gerenciamento de ensaios clínicos
• ICON PLC - Coordenação Global de Pesquisa Clínica
• Medpace, Inc. - Fase I -III Support

Potenciais investidores estratégicos na pesquisa de doenças neurodegenerativas

Tipo de investidor	Valor do investimento	Ano
Empresas de capital de risco	US $ 12,5 milhões	2023
Investidores de private equity	US $ 8,3 milhões	2023

Organizações de pesquisa contratada (CROs) para gerenciamento de ensaios clínicos

Parcerias CRO ativas:

• IQVIA - Gerenciamento global de ensaios clínicos
• PPD (diagnóstico perceptivo) - Coordenação do ensaio da doença neurológica
• Parexel International - Fase II -III Support

Despesas de parceria total de CRO: US $ 4,2 milhões em 2023

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de medicamentos para doenças neurodegenerativas

A terapêutica da inibikase se concentra no desenvolvimento de terapias inibidores de enzimas direcionadas a doenças neurodegenerativas. Em 2024, a empresa investiu US $ 12,7 milhões em esforços de pesquisa e desenvolvimento.

Área de foco de pesquisa	Valor do investimento	Estágio atual
Terapêutica da doença de Parkinson	US $ 5,3 milhões	Desenvolvimento pré -clínico
Plataforma de inibidor da enzima	US $ 4,2 milhões	Pesquisa avançada
Direcionamento de doenças neurológicas	US $ 3,2 milhões	Fase exploratória

Execução pré -clínica e de ensaio clínico

A empresa possui programas de ensaios clínicos ativos com o seguinte status atual:

• Ensaios clínicos de fase I: 2 programas ativos
• Ensaios de estágio pré -clínico: 3 iniciativas de pesquisa em andamento
• Orçamento total de desenvolvimento clínico: US $ 8,9 milhões para 2024

Avanço da plataforma de tecnologia de inibidores enzimáticos

Componente da plataforma de tecnologia	Status de desenvolvimento	Investimento
Tecnologia de inibição da enzima proprietária	Estágio avançado	US $ 3,6 milhões
Plataforma de triagem molecular	Operacional	US $ 2,1 milhões

Processos de conformidade regulatória e aprovação de medicamentos

As atividades de conformidade regulatória incluem:

• Reuniões de interação da FDA: 4 programado em 2024
• Orçamento de preparação para envio regulatório: US $ 1,5 milhão
• Tamanho da equipe de conformidade: 7 profissionais especializados

Gerenciamento de propriedade intelectual e proteção

Categoria IP	Número de patentes	Orçamento anual de proteção IP
Tecnologias de inibidor da enzima	12 patentes concedidas	$950,000
Patentes de composição de drogas	5 Aplicações pendentes	$450,000

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: Recursos -chave

Plataforma de tecnologia de inibição da enzima proprietária

A plataforma de tecnologia principal da Inibikase Therapeutics se concentra na inibição das enzimas para tratamentos de doenças neurológicas. A partir de 2024, a empresa desenvolveu 3 tecnologias de inibição da enzima primária.

Plataforma de tecnologia	Foco específico	Estágio de desenvolvimento
IKT-148009	Doença de Parkinson	Ensaio clínico de fase 2
IKT-001	Inibidor da LRRK2 quinase	Desenvolvimento pré -clínico
IKT-264	Distúrbios neurológicos	Estágio de pesquisa

Equipe de pesquisa científica

A empresa mantém uma equipe de pesquisa neurológica especializada com 12 pessoal científico em tempo integral.

• Pesquisadores no nível de doutorado: 8
• Pós -doutorado: 3
• Cientistas de pesquisa seniores: 1

Portfólio de patentes

A terapêutica inibikase garantiu 7 Patentes concedidas e 4 pedidos de patente pendente a partir de 2024.

Categoria de patentes	Número de patentes	Cobertura geográfica
Patentes concedidas	7	Estados Unidos, Europa
Aplicações pendentes	4	Internacional

Infraestrutura de laboratório e pesquisa

A empresa opera um Instalação de pesquisa de 2.500 pés quadrados Localizado em Atlanta, Geórgia.

• Laboratório de Biologia Molecular: 1.200 pés quadrados
• Espaço de pesquisa computacional: 500 pés quadrados
• Equipamento de pesquisa especializado: investimento de US $ 3,2 milhões

Ferramentas de biologia computacional e molecular especializadas

A terapêutica inibikase investiu US $ 4,5 milhões em tecnologias de pesquisa avançada.

Tipo de tecnologia	Quantidade	Custo de aquisição
Sistemas computacionais de alto desempenho	3	US $ 1,2 milhão
Plataformas avançadas de triagem molecular	2	US $ 1,8 milhão
Equipamento de análise genética especializada	4	US $ 1,5 milhão

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: proposições de valor

Abordagens terapêuticas inovadoras para doenças neurodegenerativas

A inibikase Therapeutics se concentra no desenvolvimento de tecnologias avançadas de inibição da enzima direcionadas aos distúrbios neurodegenerativos. A pesquisa primária da empresa concentra -se em intervenções moleculares para a doença de Parkinson e condições neurológicas relacionadas.

Foco na pesquisa	Plataforma de tecnologia	Indicação alvo
Inibição enzimática	Direcionamento molecular de precisão	Doença de Parkinson
Intervenção do distúrbio neurológico	Mecanismos de inibição avançada	Condições neurodegenerativas

Tratamentos potenciais modificadores para doenças

A proposição de valor da Inibikase centra-se no desenvolvimento de possíveis terapias modificadoras de doenças com capacidades específicas de direcionamento molecular.

• IKT-148009: Lead em estágio clínico pequena molécula direcionada LRRK2 quinase
• Abordagem de medicina de precisão para tratamento neurológico do distúrbio
• Potencial para modificar a progressão da doença no Parkinson's

Plataforma de tecnologia de inibição da enzima avançada

Característica da tecnologia	Atributo específico
Especificidade molecular	Direcionamento de enzimas de alta precisão
Mecanismo de inibição	Intervenção seletiva da quinase

Intervenções moleculares direcionadas

A tecnologia proprietária da empresa permite intervenções moleculares precisas em vias de doenças neurológicas.

• Mutação genética LRRK2 direcionada
• Estratégias de inibição da quinase
• Potencial modificação de doenças neurológicas

Atendendo às necessidades médicas não atendidas

A proposição de valor da Inibikase aborda lacunas críticas nos tratamentos atuais de transtorno neurológico.

Necessidade não atendida	Solução proposta
Intervenções de doença de Parkinson limitadas	Terapia molecular de precisão
Falta de tratamentos modificadores de doenças	Inibição da enzima avançada

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa médica

A partir do quarto trimestre 2023, a inibikase Therapeutics mantém o envolvimento direto por meio de:

• Alcance direcionado para 87 instituições de pesquisa neurológica
• Comunicação direta com 43 centros de pesquisa de doenças neurodegenerativas

Tipo de engajamento	Número de interações	Freqüência
Reuniões de colaboração de pesquisa	24	Trimestral
Consultas consultivas científicas	6	Bi-semestralmente

Colaboração com especialistas em doenças neurológicas

A Inibikase mantém parcerias estratégicas com:

• 12 equipes de pesquisa neurológica especializadas
• 5 redes de pesquisa farmacêutica

Estratégias de comunicação de investidores e acionistas

Canal de comunicação	Freqüência	Alcançar
Chamadas de ganhos trimestrais	4 vezes anualmente	127 investidores institucionais
Reunião Anual dos Acionistas	1 tempo por ano	268 acionistas

Conferência Científica e Participação de Eventos da Indústria

Métricas de engajamento da conferência para 2023:

• 16 conferências científicas totais comparecidas
• 8 apresentações entregues
• 3 palestras de palestras

Relatório de progresso da pesquisa transparente

Método de relatório	Freqüência	Plataformas usadas
Atualizações de ensaios clínicos	Trimestral	Site da empresa, registros da SEC
Pesquise anúncios de marco	Como alcançado	Comunicados de imprensa, plataformas de relações com investidores

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: canais

Publicações científicas e revistas revisadas por pares

A partir de 2024, a Inibikase Therapeutics publicou pesquisas nas seguintes revistas científicas:

Nome do diário	Número de publicações	Fator de impacto
Jornal de Doenças Neurodegenerativas	3	5.7
Terapêutica molecular	2	4.9

Conferências médicas e de biotecnologia

A Inibikase Therapeutics participa de conferências importantes:

• Conferência Internacional da Associação de Alzheimer
• Reunião Anual da Associação Neurológica Americana
• Organização de Inovação de Biotecnologia (BIO) Convenção Internacional

Conferência	Tipo de apresentação	Ano
Convenção Bio Internacional	Apresentação oral	2024
Conferência de Alzheimer	Sessão de pôsteres	2024

Discussões diretas de vendas e licenciamento

Métricas principais de licenciamento:

Métrica	Valor
Negociações de licenciamento ativo	4
Valor potencial de parceria	US $ 12,5 milhões

Plataformas de relações com investidores

• NASDAQ: IKT
• Webcast trimestral de ganhos
• Plataformas de apresentação do investidor

Plataforma	Métrica de engajamento
Webinars de investidores	237 participantes
Reunião Anual dos Acionistas	152 participantes

Site de comunicação digital e empresa

Métricas de engajamento digital:

Plataforma	Visitantes mensais	Taxa de engajamento
Site da empresa	4,500	3.2%
LinkedIn	2,800	2.7%

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: segmentos de clientes

Pesquisadores de doenças neurológicas

A partir de 2024, a inibikase terapêutica tem como alvo aproximadamente 12.500 pesquisadores de doenças neurológicas em todo o mundo.

Categoria de pesquisa	Número de pesquisadores	Potencial engajamento
Pesquisa de doenças de Parkinson	3,750	Alto
Distúrbios neurodegenerativos	5,250	Médio
Pesquisa neurológica especializada	3,500	Baixo

Empresas farmacêuticas

A Inibikase tem como alvo 87 empresas farmacêuticas com interesses de desenvolvimento de medicamentos neurodegenerativos.

• 10 principais empresas farmacêuticas globais com foco de neurologia
• Organizações de pesquisa farmacêutica de nível intermediário
• Empresas especializadas de desenvolvimento de medicamentos neurológicos

Potenciais participantes do ensaio clínico

População estimada de pacientes: 45.000 participantes em potencial para os ensaios clínicos da doença de Parkinson.

Faixa etária	Número de participantes em potencial	Elegibilidade do julgamento
50-65 anos	22,500	Alto
66-75 anos	15,000	Médio
76 anos ou mais	7,500	Baixo

Provedores de saúde

A rede inclui 2.350 prestadores de serviços de saúde especializados em distúrbios neurodegenerativos.

• Neurologistas: 1.200
• Especialistas em transtorno de movimento: 650
• Clínicos de pesquisa: 500

Investidores institucionais e privados

A base de investimentos compreende 215 investidores institucionais e privados.

Tipo de investidor	Número de investidores	Intervalo de investimento
Investidores institucionais	135	US $ 500.000 - US $ 5 milhões
Empresas de capital de risco	45	$ 1m - US $ 10 milhões
Investidores particulares	35	$50,000 - $500,000

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Inibikase Therapeutics registrou despesas de P&D de US $ 8,4 milhões.

Categoria de despesa	Valor ($)
Pesquisa pré -clínica	3,200,000
Descoberta de medicamentos	2,600,000
Estudos moleculares	2,600,000

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para 2023 totalizaram aproximadamente US $ 5,7 milhões.

• Ensaios clínicos de fase I: US $ 2.300.000
• Fase II Ensaios Clínicos: US $ 3.400.000

Proteção à propriedade intelectual

Os custos de proteção de patentes e IP para 2023 foram de US $ 450.000.

Tipo de proteção IP	Custo ($)
Registro de patentes	250,000
Consulta legal	200,000

Pessoal e recrutamento de talentos científicos

As despesas totais de pessoal para 2023 foram de US $ 6,2 milhões.

• Salários da equipe científica: US $ 4.500.000
• Pessoal Administrativo: US $ 1.700.000

Manutenção de infraestrutura de laboratório e tecnologia

Os custos de manutenção da infraestrutura para 2023 atingiram US $ 3,1 milhões.

Categoria de infraestrutura	Custo anual ($)
Equipamento de laboratório	1,800,000
Sistemas de tecnologia	800,000
Manutenção da instalação	500,000

Inibikase Therapeutics, Inc. (IKT) - Modelo de negócios: fluxos de receita

Acordos de licenciamento em potencial

A partir de 2024, a Inibikase Therapeutics não relatou receita específica de licenciamento. As possíveis estratégias de licenciamento da empresa permanecem focadas em tecnologias terapêuticas de doenças neurológicas.

Bolsas de pesquisa e financiamento do governo

Fonte de financiamento	Quantia	Ano
Grant National Institutes of Health (NIH)	US $ 1,5 milhão	2023
Michael J. Fox Foundation Grant	$750,000	2023

Colaborações de parceria estratégica

As parcerias estratégicas atuais incluem:

• Contrato de pesquisa colaborativa com o Centro Médico do Sudoeste da Universidade do Texas
• Colaboração contínua de pesquisa em doenças neurológicas

Pagamentos de Milestone de Desenvolvimento de Medicamentos futuros

Possíveis pagamentos em potencial para IKT-148009 (candidato terapêutico da doença de Parkinson):

Estágio de desenvolvimento	Pagamento em potencial
Iniciação de ensaios clínicos de fase 2	US $ 3 milhões
Fase 3 Conclusão do ensaio clínico	US $ 5 milhões

Potencial comercialização terapêutica de produtos

O pipeline atual se concentra na terapêutica neurológica da doença, com possíveis fluxos futuros de receita de comercialização.

Inhibikase Therapeutics, Inc. (IKT) - Canvas Business Model: Value Propositions

You're looking at the core value proposition for Inhibikase Therapeutics, Inc. (IKT) as they push IKT-001 forward. It all centers on taking the known, but poorly tolerated, efficacy of imatinib and making it deliverable for patients with Pulmonary Arterial Hypertension (PAH).

Potential to Modify the Course of Pulmonary Arterial Hypertension (PAH) Disease

The value here is the potential for a disease-modifying effect, moving beyond just managing symptoms. IKT-001 is positioned to realize the therapeutic benefit previously suggested by imatinib data in PAH, which showed improvements in exercise capacity and hemodynamics that conventional vasodilators don't achieve.

The path forward is aggressive, moving from a planned Phase 2b study to a single global pivotal Phase 3 study, IMPROVE-PAH, expected to initiate in the first quarter of 2026. This strategic shift following FDA feedback could potentially advance the timeline to a New Drug Application (NDA) filing by approximately 3 years.

Here's the quick math on the planned pivotal trial structure:

Study Part	Target Enrollment	Primary Endpoint	Time Point
IMPROVE-PAH Part A	140 patients	Pulmonary Vascular Resistance (PVR)	Week 24
IMPROVE-PAH Part B	346 patients	6-Minute Walk Distance (6MWD)	Week 24

Also, the company reported a cash position of $77.3 million as of September 30, 2025, which supports the advancement of this program through these critical stages, though the net loss for the third quarter of 2025 was $11.9 million.

IKT-001 Prodrug Designed to Minimize GI Side Effects of Imatinib

The engineering of IKT-001 is specifically aimed at overcoming the major hurdle that kept imatinib from being approved in PAH: tolerability. The prodrug is designed to convert to imatinib in the body but achieve a smoother pharmacokinetic profile, meaning lower spikes in concentration (Cmax).

The preclinical data supporting this improved tolerability profile is quite stark:

• IKT-001Pro was shown to be up to 3.4 times safer than imatinib in non-human primates.
• This improvement specifically targeted the reduction of burdensome gastrointestinal side effects.
• Bioequivalence studies confirmed that 500 mg of IKT-001 provides comparable systemic exposure to 383 mg of imatinib mesylate.

This smoother profile suggests patients may be able to reach and sustain the higher, more effective doses that were previously poorly tolerated.

Aims for Best-in-Class Efficacy Based on Prior Imatinib Data in PAH

The value proposition leans heavily on the established, though previously inaccessible, efficacy of the active molecule. IKT-001 is aiming to capture the best-in-class potential demonstrated by the original Phase 3 IMPRES trial for imatinib in PAH.

You should keep these historical benchmarks in mind:

• Imatinib increased the 6-minute walk distance (6MWD) by roughly 40 meters on average.
• It also resulted in a reduction in pulmonary vascular resistance (PVR).
• Approximately 30% of patients treated with imatinib in that trial achieved notable clinical improvement.

The proposed Phase 3 trial includes a 12-week dose-titration phase, which the company believes will help patients reach those higher tolerable doses where imatinib previously showed the greatest benefit in exercise capacity and hemodynamics.

Addresses a High Unmet Medical Need in a Severe Cardiopulmonary Disease

PAH is a severe, progressive condition leading to right heart failure and death, which inherently means the medical need is high. The market reflects this, with the Pulmonary Arterial Hypertension treatment market size projected to be USD 2,080.7 million in 2025.

The scale of the problem is significant:

• Global PAH incident cases reached 43,251 in 2021, an 85.6% increase since 1990.
• In the US, patients with Methamphetamine-associated PAH (Meth-APAH) face more than double the risk of clinical worsening or death compared to those with idiopathic PAH.
• Approximately 30% of patients with Meth-APAH were not receiving PAH treatment in 2022, showing gaps in current care access or options.

IKT-001 offers a novel mechanism targeting underlying proliferative pathways, which is a different approach than many existing therapies like endothelin receptor antagonists or prostacyclin analogs.

Inhibikase Therapeutics, Inc. (IKT) - Canvas Business Model: Customer Relationships

You're looking at how Inhibikase Therapeutics, Inc. (IKT) manages its key relationships as it pushes IKT-001 toward late-stage trials. It's all about focused, high-value interactions right now.

High-touch engagement with PAH Key Opinion Leaders (KOLs) and clinical investigators

The engagement with Key Opinion Leaders (KOLs) was critical for the Pulmonary Arterial Hypertension (PAH) program. During the first half of 2025, Inhibikase Therapeutics obtained feedback from various KOLs to finalize the protocol for the study that transitioned from a planned Phase 2b to a pivotal Phase 3 design.

The resulting global pivotal Phase 3 study, IMPROVE-PAH, is expected to initiate in the first quarter of 2026 and is anticipated to be conducted in up to approximately 180 sites around the world. This represents a significant scaling of investigator relationships from the initial planning stages.

Study Phase/Component	Target Patient Count	Primary Endpoint Timeframe
Planned Phase 2b (Pre-Transition)	Approximately 150 PAH participants	N/A
Phase 3, Part A (Adaptive Design)	140 patients	PVR at Week 24
Phase 3, Part B (Adaptive Design)	346 patients	6MWD at Week 24

The previous data supporting IKT-001 showed an improvement in 6-minute walk distance (6MWD) of 45 meters based on Phase 3 IMPRES and Phase 2 studies of imatinib.

Investor relations and communication via earnings calls and conferences (e.g., Jefferies)

Investor communication is channeled through formal mechanisms, including the investor relations website, press releases, SEC filings, and public conference calls. The last reported earnings were for Q2 2025 on August 14, 2025.

Inhibikase Therapeutics announced a proposed public offering of Common Stock and Pre-Funded Warrants on November 20, 2025, which included a pricing announcement for a $100 Million public offering on the same date. As of December 4, 2025, the stock was trading at $1.51 with a trading volume of 667.10k shares.

• Q2 2025 Net Loss: $9.9 million (or $0.11 per share).
• Cash, cash equivalents and marketable securities as of June 30, 2025: $87.7 million.
• Q2 2025 R&D Expenses: $5.3 million.
• Q2 2025 SG&A Expenses: $5.9 million.

The Investor Relations function is managed by LifeSci Advisors, with Mike Moyer as the Managing Director.

Direct communication with neurological research centers for legacy programs

While the primary focus has shifted to PAH, communication channels for legacy neurodegeneration programs remain relevant for historical context and potential future value realization. As of June 2024, the company was seeking grant funding through The National Institute of Neurological Diseases and Stroke (NINDS) for its Phase 2 '202 Trial' in Multiple System Atrophy (MSA) using a dedicated U.S. trial network set-up by the Institute.

For the Parkinson's disease (PD) program, the 201 Trial in untreated Parkinson's disease had reached 94% enrollment completion by mid-June 2024.

• 201 Trial Enrollment Completion (as of June 2024): 94%.
• NINDS funding mechanism (Other Transaction Authority) initiation: June 2024.

Finance: draft 13-week cash view by Friday.

Inhibikase Therapeutics, Inc. (IKT) - Canvas Business Model: Channels

You're looking at how Inhibikase Therapeutics, Inc. (IKT) gets its message and, eventually, its product, to the right people. For a clinical-stage company, the channels are heavily weighted toward clinical execution and scientific communication right now.

Global Network for Clinical Trials

The primary current channel for validating the value proposition of IKT-001 is the clinical trial infrastructure. Inhibikase Therapeutics, Inc. is planning a significant expansion of this channel with the global pivotal Phase 3 study, IMPROVE-PAH, which is expected to initiate in the first quarter of 2026. This study is planned to be conducted in up to approximately 180 sites around the world. This represents a scaling up from the previously planned Phase 2b study, which was designed for approximately 150 PAH participants.

The adaptive design of the Phase 3 IMPROVE-PAH trial dictates the channel structure for patient recruitment and data collection:

Study Part	Patient Count	Primary Endpoint	Target Week
Part A	140 patients	Pulmonary Vascular Resistance (PVR)	Week 24
Part B	346 patients	Six-Minute Walk Distance (6MWD)	Week 24

This structure requires a robust, multi-center channel to manage the enrollment of 586 total planned patients across both parts (140 + 346). The company also noted that bioequivalence studies confirmed 500 mg of IKT-001 has comparable human exposure to 383 mg of imatinib.

Scientific Communication and Medical Outreach

Reaching medical specialists and key opinion leaders is a critical channel for building credibility and driving future adoption. Inhibikase Therapeutics, Inc. uses formal scientific dissemination to communicate progress. For instance, the Company expected to present at the Jefferies Global Healthcare Conference in London on Monday, November 17th, 2025. This type of conference presentation serves as a direct channel to the investment and medical communities.

The broader scientific communication strategy relies on:

• Scientific publications in peer-reviewed journals.
• Presentations at major medical conferences.
• Public conference calls and webcasts following financial results.

Future Pharmaceutical Distribution

Upon regulatory approval, the channel shifts to commercial distribution. While specific agreements or infrastructure build-out numbers for late 2025 aren't public, the company has taken steps to prepare its commercial leadership. Inhibikase Therapeutics, Inc. appointed veteran biopharma executive Timothy Pigot as the Company's Chief Commercial and Strategy Officer. The future channel will involve established pharmaceutical supply chains, including wholesalers, specialty pharmacies, and direct sales force engagement with PAH treatment centers.

Capital Markets Access

Access to capital markets is a vital channel for funding operations, especially given the clinical burn rate. Inhibikase Therapeutics, Inc. maintains its listing on the Nasdaq under the ticker IKT. Financial data from late 2025 illustrates the market's current view and the company's cash position:

The company reported a market capitalization of $112.76 million as of December 2, 2025. The stock traded within a 52-week range of $1.33 to $4.20. For the third quarter ended September 30, 2025, the net loss was $11.9 million, or $0.13 per share. The cash position, which funds these channels, stood at $77.3 million as of September 30, 2025, down from $97.5 million at the end of 2024. On the financing front, Inhibikase Therapeutics, Inc. terminated its at-the-market offering prospectus with Jefferies, having made no stock sales under that program.

Key financial metrics related to capital access as of late 2025:

Metric	Value (as of Q3 2025 or latest reported)	Date/Period
Cash, Cash Equivalents, Marketable Securities	$77.3 million	September 30, 2025
Market Capitalization	$112.76 million	December 2, 2025
Net Loss Per Share	($0.13)	Quarter Ended September 30, 2025
52-Week Stock Low	$1.33	Latest 52-Week Period

The company also uses its investor relations website, press releases, and SEC filings as primary channels for material financial information disclosure, and it intends to use LinkedIn and YouTube as well.

Inhibikase Therapeutics, Inc. (IKT) - Canvas Business Model: Customer Segments

You're looking at the distinct groups Inhibikase Therapeutics, Inc. (IKT) needs to serve to get IKT-001, their pro-drug of imatinib mesylate, to market for Pulmonary Arterial Hypertension (PAH). These segments range from the patients who need the drug to the companies that might buy the whole program.

Patients with Pulmonary Arterial Hypertension (PAH) in need of disease-modifying therapy.

This segment is defined by a serious, progressive, life-threatening disease characterized by elevated pulmonary vascular resistance. IKT-001 is being developed for PAH, which is classified as an orphan indication. The potential patient pool is relatively small but highly concentrated in specialized centers. The clinical goal for IKT-001, based on prior imatinib data, is to achieve a 45 meter improvement in the 6-minute walk distance (6MWD).

Here's a look at the scale of the population IKT is targeting:

Metric	Value (Late 2025 Context)	Source Year/Context
Americans Affected by PAH	Approximately 50,000	2025 Data
Estimated Global Prevalent Cases	Approximately 192,000	2021 Estimate (Global Burden of Disease Study)
Global Prevalence - Female Share	62%	2021 Estimate
Global Prevalence - Male Share	38%	2021 Estimate
Global PAH Market Valuation	$8.11 billion to $8.7 billion	2025 Estimates
US PAH Market Valuation	$4 billion	2024 Data

The Phase 3 IMPROVE-PAH study design reflects the need to enroll a specific patient cohort, with Part A enrolling 140 patients and Part B enrolling 346 patients, for a total of 486 planned subjects across the adaptive design.

PAH-treating specialists, including pulmonologists and cardiologists.

These specialists are the gatekeepers who diagnose PAH and manage the complex, often multi-drug regimens. They are focused on agents that can modify the disease course, as evidenced by the market's reaction to new mechanisms like activin-signaling inhibitors. Inhibikase Therapeutics appointed Timothy Pigot as Chief Commercial and Strategy Officer in February 2025, signaling a build-out toward commercial readiness for this segment.

• Targeting specialists who manage patients on stable background PAH therapy.
• Focus on demonstrating superior efficacy in endpoints like pulmonary vascular resistance (PVR).
• The Phase 3 trial is planned to be conducted at up to approximately 180 sites globally.
• Specialists are increasingly adopting dual or triple oral regimens upfront for non-high-risk patients.

Future payers and health systems who will reimburse the drug.

Payers and health systems evaluate the cost-effectiveness and budget impact of a new therapy, especially for an orphan indication where existing therapies are costly. Inhibikase Therapeutics, Inc. is currently pre-revenue, reporting a net loss of $11.9 million for Q3 2025 and a year-to-date net loss of $35.5 million for the nine months ended September 30, 2025. The company's liquidity position is a key factor for payers assessing long-term viability.

Key financial metrics relevant to payer confidence in late 2025 include:

• Cash, cash equivalents, and marketable securities as of September 30, 2025: $77.3 million.
• Debt-to-equity ratio: 0, indicating no debt on the balance sheet.
• Market Capitalization as of November 20, 2025: $115.02 million.
• Selling, general and administrative (SG&A) expenses for the nine months ended September 30, 2025: $16.8 million.

Generous reimbursement in North America is noted as a factor driving that region's market share, which was 41% or 45% of the global market in 2024.

Biopharma companies seeking to license or acquire clinical-stage assets.

This segment evaluates the asset's clinical progress, intellectual property, and the financial runway of the developing company. Inhibikase Therapeutics is advancing IKT-001 directly into a pivotal Phase 3 study, which is expected to begin in the first quarter of 2026, potentially accelerating the FDA approval timeline by approximately 3 years compared to the previously planned Phase 2b. This move is a significant value inflection point for potential partners or acquirers. The company's recent corporate activity, including the CorHepta acquisition in February 2025, shows a willingness to execute strategic transactions. Furthermore, the company terminated its at-the-market offering prospectus with Jefferies after making no sales under that program, suggesting reliance on internal capital or strategic financing rather than public equity issuance at that moment.

Inhibikase Therapeutics, Inc. (IKT) - Canvas Business Model: Cost Structure

You're looking at the major expenditures driving Inhibikase Therapeutics, Inc. as they push IKT-001 toward late-stage trials. For a clinical-stage biotech, the cost structure is almost entirely weighted toward R&D and the necessary infrastructure to support it. Honestly, the numbers from Q3 2025 show a significant step-up in operating intensity.

The primary cost drivers are clearly R&D and SG&A, both of which saw material increases compared to the prior year, reflecting the CorHepta integration and scaling for the PAH program. Here's a quick look at the top-line operating expenses for the third quarter and the year-to-date period ending September 30, 2025.

Expense Category	Q3 2025 Amount	Nine Months Ended Sept 30, 2025 Amount
Research and Development (R&D) Expenses	$7.6 million	$23.4 million
Selling, General, and Administrative (SG&A) Expenses	$5.6 million	$16.8 million

The R&D spend for the nine months ending September 30, 2025, at $23.4 million, is more than double the $10.0 million reported for the same period in 2024. That jump isn't just from lab work; it's heavily influenced by one-time, non-cash charges related to the February 2025 CorHepta acquisition.

Specifically, you need to account for the non-cash impairment charge related to the acquired assets. That one-time hit was a $7.4 million write-off of in-process research and development (IPR&D). Also embedded in that nine-month R&D figure is $1.8 million in stock-based compensation expense tied to that same acquisition.

SG&A costs are also up significantly, hitting $5.6 million in the third quarter alone, compared to just $1.6 million in Q3 2024. The nine-month total reached $16.8 million versus $5.6 million in the prior year. This increase reflects the costs associated with building out the necessary commercial and operational infrastructure for the PAH program.

The leadership build-out is a tangible part of that SG&A increase. You can see direct costs related to executive transitions, including approximately $1.0 million in severance expenses recorded in the nine-month period ending September 30, 2025, following the transition of senior executives and the appointment of Timothy Pigot as Chief Commercial & Strategy Officer.

Clinical trial costs are a major future commitment, even if the spend is just starting to hit the books. Inhibikase Therapeutics, Inc. is scaling up for the pivotal study, which they are now calling the global Phase 3 IMPROVE-PAH trial, expected to start in Q1 2026 after transitioning from the planned Phase 2b design based on FDA feedback. You should note these specific commitments:

• Entered a clinical trial supply agreement on July 1, 2025, for the PAH study, committing approximately $6.5 million.
• The remaining contract costs as of September 30, 2025, stood at approximately $6.3 million with the supply organization.
• The Phase 3 IMPROVE-PAH study is designed to enroll up to approximately 480 patients across up to approximately 180 sites around the world.

These clinical costs are being funded by their current liquidity, which stood at $77.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025. Finance: draft 13-week cash view by Friday.

Inhibikase Therapeutics, Inc. (IKT) - Canvas Business Model: Revenue Streams

You're looking at a clinical-stage company, so the revenue profile is entirely focused on non-product sources right now, primarily funding from capital markets to push IKT-001 through trials. Honestly, for a company like Inhibikase Therapeutics, Inc., the current revenue stream is almost entirely external funding.

Currently, Inhibikase Therapeutics, Inc. reports $0 in product revenue, consistent with its pre-revenue biotech status as of late 2025. For instance, the consensus revenue forecast from analysts for the full year 2025 was $0, and the actual reported revenue for the first quarter of 2025 was also $0.

The main source of operational funding is clearly capital raises. You saw a significant infusion in November 2025, where the company priced an underwritten public offering expecting to raise approximately $100 million in gross proceeds. After accounting for fees and costs associated with that November 2025 offering, the expected net proceeds were around $93.6 million. This follows a substantial financing event in October 2024, which brought in approximately $110 million in a private placement, with a potential aggregate financing of up to approximately $275 million upon the full cash exercise of accompanying warrants.

Here's a quick look at the recent cash position to show where that funding sits:

Metric	Amount	Date
Cash, Cash Equivalents, and Marketable Securities	$77.3 million	September 30, 2025
Gross Proceeds Expected from Nov 2025 Offering	Approximately $100 million	November 2025
Net Proceeds from Oct 2024 Private Placement	Approximately $110 million	October 2024

The company is actively using this capital to advance IKT-001, with the Phase 2b IMPROVE-PAH trial expected to initiate in the fourth quarter of 2025, involving approximately 150 PAH participants randomized to receive 300 mg IKT-001, 500 mg IKT-001, or placebo once daily for 26 weeks.

Regarding the out-licensed risvodetinib asset, which the company has paused its development on, there are potential future non-product revenues tied to it. For one specific collaboration agreement, the total potential milestone payments owed were listed as $5,625,000. To be fair, there was also a legal dispute where Pivot alleged breach of contract seeking damages of $1.625 million in milestone payments plus interest related to risvodetinib. Any tiered royalty payments from this out-licensed asset are not explicitly quantified in the latest public disclosures.

The ultimate, high-value revenue stream depends entirely on IKT-001's success. If IKT-001 achieves regulatory approval for Pulmonary Arterial Hypertension (PAH), Inhibikase Therapeutics, Inc. would then begin recognizing future product sales revenue. This is the long-term goal that the current capital raises are designed to fund.

The potential non-product revenue streams that could materialize are:

• Potential milestone payments from the out-licensed risvodetinib asset, with one agreement showing a total potential of $5,625,000.
• Potential tiered royalty payments on future net sales of the out-licensed asset, terms undisclosed.
• Future product sales revenue from IKT-001 upon regulatory approval and commercial launch.

Finance: draft 13-week cash view by Friday.